%0 Journal Article %1 Motzer.2007 %A Motzer, R. J. %A Michaelson, M. D. %A Rosenberg, J. %A Bukowski, R. M. %A Curti, B. D. %A George, D. J. %A Hudes, G. R. %A Redman, B. G. %A Margolin, K. A. %A Wilding, G. %D 2007 %J J.Urol. %K & Administration Adult Aged Agents Antineoplastic Carcinoma Cell Disease Disease-Free Female Follow-Up Humans Indoles Kidney Laboratories Male Method Middle Neoplasm Neoplasms Oral Outcome Progression Pyrroles Rate Renal Research Retrospective Single-Blind Staging States Studies Survival Treatment Tyrosine United administration dosage drug epidemiology methods mortality pathology response therapy %N 5 %P 1883-1887 %T Sunitinib efficacy against advanced renal cell carcinoma %U PM:17868732 %V 178 %X PURPOSE: We assessed the efficacy of the oral multitargeted tyrosine kinase inhibitor sunitinib in patients with metastatic clear cell renal cell carcinoma. MATERIALS AND METHODS: Patients with metastatic clear cell renal cell carcinoma were enrolled in this multicenter, phase II clinical trial. Major eligibility requirements were clear cell renal cell carcinoma histology, prior nephrectomy, measurable metastases and failed prior cytokine therapy as a result of disease progression. Sunitinib was given orally as second line therapy in 6-week cycles of 50 mg daily for 4 weeks, followed by 2 weeks off drug per treatment cycle. Response to sunitinib was rigorously assessed by an independent third party core imaging laboratory (central review). RESULTS: Of 106 patients enrolled in the study 105 were evaluated for response. As determined by independent third party assessment, the objective response rate was 33% (95% CI 24%-43%) with a median response duration of 14.0 months. Median time to p

@article{Motzer.2007, abstract = {PURPOSE: We assessed the efficacy of the oral multitargeted tyrosine kinase inhibitor sunitinib in patients with metastatic clear cell renal cell carcinoma. MATERIALS AND METHODS: Patients with metastatic clear cell renal cell carcinoma were enrolled in this multicenter, phase II clinical trial. Major eligibility requirements were clear cell renal cell carcinoma histology, prior nephrectomy, measurable metastases and failed prior cytokine therapy as a result of disease progression. Sunitinib was given orally as second line therapy in 6-week cycles of 50 mg daily for 4 weeks, followed by 2 weeks off drug per treatment cycle. Response to sunitinib was rigorously assessed by an independent third party core imaging laboratory (central review). RESULTS: Of 106 patients enrolled in the study 105 were evaluated for response. As determined by independent third party assessment, the objective response rate was 33% (95% CI 24%-43%) with a median response duration of 14.0 months. Median time to p}, added-at = {2010-02-05T11:28:39.000+0100}, author = {Motzer, R. J. and Michaelson, M. D. and Rosenberg, J. and Bukowski, R. M. and Curti, B. D. and George, D. J. and Hudes, G. R. and Redman, B. G. and Margolin, K. A. and Wilding, G.}, biburl = {https://www.bibsonomy.org/bibtex/230fd986fa9ab1ed24fcf59cfe32f7d3c/kanefendt}, interhash = {8cb507f3b571cf90ed95fcf6614069d4}, intrahash = {30fd986fa9ab1ed24fcf59cfe32f7d3c}, journal = {J.Urol.}, keywords = {& Administration Adult Aged Agents Antineoplastic Carcinoma Cell Disease Disease-Free Female Follow-Up Humans Indoles Kidney Laboratories Male Method Middle Neoplasm Neoplasms Oral Outcome Progression Pyrroles Rate Renal Research Retrospective Single-Blind Staging States Studies Survival Treatment Tyrosine United administration dosage drug epidemiology methods mortality pathology response therapy}, number = 5, pages = {1883-1887}, timestamp = {2010-02-05T11:28:57.000+0100}, title = {Sunitinib efficacy against advanced renal cell carcinoma}, url = {PM:17868732}, volume = 178, year = 2007 }